专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP1951865A4 STABILIZING FORMULATIONS FOR RECOMBINANT VIRUSES 审中-公开
标题翻译：稳定价格配方重组病毒
公开(公告)号：EP1951865A4
公开(公告)日：2010-06-23
申请号：EP06804724
申请日：2006-11-15
申请人： SANOFI PASTEUR LTD
发明人： CIGARINI SANDRINE
IPC分类号： C12N7/00 , A61K39/00 , A61K48/00 , A61P31/00 , A61P35/00 , C12N1/04 , C12N7/01 , C12N15/86
CPC分类号： A61K39/0011 , A61K39/12 , A61K47/18 , A61K47/183 , A61K47/26 , A61K47/32 , A61K2039/5256 , C12N7/00 , C12N2710/24021 , C12N2710/24041 , C12N2710/24051
摘要： This invention relates to preparations of viruses, e.g. for vaccine or other pharmaceutical or research use, to their stabilization, and to processes of producing such preparations, as well as to their use, e.g. as vaccines or as virus vectors. The formulations comprise a sugar, a preservative, a dispersing agent, a thermal stability agent, a buffer, and up to three distinct types of amino acids without impacting the structural appearance of the lyophilized product.

2. 发明授权

EP0538496B1 Recombinant fowlpox virus with intact FPV-tk-gene 失效
标题翻译：含禽痘病毒重组完整FPV tk基因
公开(公告)号：EP0538496B1
公开(公告)日：2003-10-29
申请号：EP91114300.6
申请日：1991-08-26
申请人： Baxter Healthcare S.A.
发明人： Dorner, Friedrich, Prof. Dr. , Scheiflinger, Friedrich, Dipl.-Ing. , Falkner, Falko Günter, Dr.
IPC分类号： C12N15/86 , C12N15/85 , C12N15/39 , A61K39/00
CPC分类号： C12N15/86 , A61K48/00 , A61K2039/5256 , C12N2710/24021 , C12N2710/24043

3. 发明公开

EP3089756A4 POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND METHODS OF MAKING AND USING SAME 无效
标题翻译： POCKENVIRUS-PLASMODIUMREKOMBINANTEN，ZUSAMMENSETZUNGEN MIT SOLCHEN REKOMBINANTEN，VERWENDUNGEN DAVON UND VERFAHREN ZUR HERSTELLUNG UND VERWENDUNG DAVON
公开(公告)号：EP3089756A4
公开(公告)日：2017-08-16
申请号：EP14877230
申请日：2014-12-19
申请人： V-CORE TECH INC
发明人： PAOLETTI ENZO , WEINBERG RANDALL L , GOEBEL SCOTT J
IPC分类号： A61K39/275 , A61K39/015 , A61P37/00 , C12N15/86
CPC分类号： C12N7/00 , A61K39/015 , A61K39/275 , A61K2039/5256 , C12N15/86 , C12N2710/24021 , C12N2710/24034 , C12N2710/24122 , C12N2710/24134 , C12N2710/24143
摘要： The invention provides a recombinant or synthetic or engineered or non-naturally occurring poxvirus that contains and expresses DNA encoding a heterologous or exogenous antigen, epitope or immunogen and Flagellin or an operable binding portion thereof. The poxvirus can contain or be engineered to contain and express vaccinia host range gene K1L. The poxvirus can be attenuated as to mammals, e.g., NYVAC, NYVAC.1, NYVAC.2, avipox, canarypox, fowlpox, ALVAC, TROVAC, MVA, or MVA-BN. The invention also provides methods for inducing an immunological response involving the poxvirus, and compositions containing the poxvirus. The antigen, epitope or immunogen that the poxvirus expresses can be at least one Plasmodium antigen. The Plasmodium antigen(s), epitope(s) or immunogen(s) can be SERA, ABRA, Pfhsp70, AMA-1, Pfs25, Pfs16, CSP, PfSSP2, LSA-1 repeatless, MSA-1, AMA-1 or combination(s) thereof. Advantageously the poxvirus contains DNA coding for and expresses Plasmodium antigen(s) CSP, PfSSP2, LSA-1-repeatless, MSA-1, SERA, AMA-1 and Pfs25. Also, advantageously, the poxvirus is a NYVAC poxvirus. The invention thus also provides an anti-malarial immunogenic or immunological compositions comprising the poxvirus, and methods for inducing an immunogenic or immunological response against malaria or Plasmodium in a mammal comprising administering to the mammal the poxvirus or an immunological or immunogenic composition containing the poxvirus. The mammal can be a human.
摘要翻译：本发明提供了包含和表达编码异源或外源抗原，表位或免疫原和鞭毛蛋白或其可操作的结合部分的DNA的重组或合成或工程化或非天然存在的痘病毒。痘病毒可以含有或被工程化为含有和表达牛痘宿主范围基因K1L。关于哺乳动物，例如NYVAC，NYVAC.1，NYVAC.2，禽痘病毒，金丝雀痘病毒，禽痘病毒，ALVAC，TROVAC，MVA或MVA-BN，痘病毒可以减毒。本发明还提供了诱导涉及痘病毒的免疫学应答的方法，以及含有痘病毒的组合物。痘病毒表达的抗原，表位或免疫原可以是至少一种疟原虫抗原。疟原虫抗原，表位或免疫原可以是SERA，ABRA，Pfhsp70，AMA-1，Pfs25，Pfs16，CSP，PfSSP2，LSA-1无重复，MSA-1，AMA-1或组合（s）。有利的是，痘病毒含有编码和表达疟原虫抗原CSP，PfSSP2，LSA-1-重复序列，MSA-1，SERA，AMA-1和Pfs25的DNA。而且，有利地，痘病毒是NYVAC痘病毒。本发明因此还提供了包含痘病毒的抗疟疾免疫原性或免疫学组合物，以及在哺乳动物中诱导针对疟疾或疟原虫的免疫原性或免疫应答的方法，包括给予哺乳动物痘病毒或含有痘病毒的免疫学或免疫原性组合物。哺乳动物可以是人类。

4. 发明公开

EP2983704A1 FUSION POLYPEPTIDES AND VACCINES 有权
标题翻译： FUSIONSPOLYPEPTIDE UND IMPFSTOFFE
公开(公告)号：EP2983704A1
公开(公告)日：2016-02-17
申请号：EP14716818.1
申请日：2014-04-10
申请人： Ceva Sante Animale
发明人： SATO, Takanori
IPC分类号： A61K39/12 , A61K39/385
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/385 , A61K2039/552 , A61K2039/6075 , C07K2319/02 , C12N7/00 , C12N2710/24021 , C12N2710/24043 , C12N2710/24122 , C12N2750/10022 , C12N2750/10034 , C12N2750/10071
摘要： The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids,vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection.
摘要翻译：本发明涉及新型免疫原性多肽及其在疫苗组合物中的用途。本发明还涉及表达多肽的核酸，载体和细胞及其用途。本发明的多肽更具体地包含衍生自B5R基因的免疫原结构域和细胞膜寻址结构域。本发明特别适用于生产用于非人类动物的疫苗，特别是针对PCV2感染的猪接种疫苗。

5. 发明公开

EP2789346A1 Fusion polypeptides and vaccines 审中-公开
标题翻译：融合多肽和Impfstoffe
公开(公告)号：EP2789346A1
公开(公告)日：2014-10-15
申请号：EP13163299.4
申请日：2013-04-11
申请人： CEVA Santé Animale SA
发明人： Sato, Takanori
IPC分类号： A61K39/12 , A61K39/385
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/385 , A61K2039/552 , A61K2039/6075 , C07K2319/02 , C12N7/00 , C12N2710/24021 , C12N2710/24043 , C12N2710/24122 , C12N2750/10022 , C12N2750/10034 , C12N2750/10071
摘要： The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids, vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection.
摘要翻译：本发明涉及新型免疫原性多肽及其在疫苗组合物中的用途。本发明还涉及表达多肽的核酸，载体和细胞及其用途。本发明的多肽更具体地包含衍生自B5R基因的免疫原结构域和细胞膜寻址结构域。本发明特别适用于生产用于非人类动物的疫苗，特别是针对PCV2感染的猪接种疫苗。

6. 发明公开

EP3307330A1 METHOD OF TREATMENT USING ONCOLYTIC VIRUSES 有权
标题翻译：使用溶瘤病毒的治疗方法
公开(公告)号：EP3307330A1
公开(公告)日：2018-04-18
申请号：EP16812381.8
申请日：2016-06-15
申请人： New York University
发明人： MOHR, Ian J.
IPC分类号： A61K48/00 , A61P35/00
CPC分类号： A61K35/768 , A61K38/19 , C07K14/005 , C12N7/00 , C12N2710/24021 , C12N2710/24122 , C12N2710/24132 , C12N2710/24221 , C12N2710/24222 , A61K2300/00
摘要： A method for treating a tumor by administering to a subject in need of such treatment an effective amount for treating the tumor of a Poxviridae decapping deficient mutant virus. Also disclosed are mutant Poxviridae and pharmaceutical formulations for use in the method.

7. 发明公开

EP3074517A1 COMPOSITIONS AND METHODS VECTORS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS VECTORS 有权
标题翻译：合剂和方法，向量给有痘病毒载体改进的免疫反应
公开(公告)号：EP3074517A1
公开(公告)日：2016-10-05
申请号：EP14806215.1
申请日：2014-11-25
申请人： Bavarian Nordic A/S
发明人： HAUSMANN, Jürgen , WOLFERSTÄTTER, Michael
IPC分类号： C12N15/86
CPC分类号： C12N15/117 , A61K39/39 , A61K2039/55561 , C12N7/00 , C12N15/86 , C12N2310/17 , C12N2310/53 , C12N2330/51 , C12N2710/24021 , C12N2710/24043 , C12N2710/24063
摘要： Provided herein are recombinant poxviruses comprising heterologous or native nucleic acids specifying excess double-stranded RNA (dsRNA) early in infection, which may further comprise heterologous nucleic acids encoding one or more costimulatory molecules, and/or heterologous nucleic acids encoding one or more infectious disease-associated antigens or tumor-associated antigens, as well as pharmaceutical compositions comprising such recombinant poxviruses and methods and uses thereof. The recombinant poxviruses provided herein enhance innate and adaptive immune activation in subjects compared to identical recombinant poxviruses lacking heterologous or native transcription units specifying excess early dsRNA.
摘要翻译：提供在是包含异源或天然核酸指定过量的双链RNA（dsRNA的）在感染早期，其还可包含异源核酸编码一种或多种共刺激分子，和/或异源核酸编码一种或多种感染性疾病的重组痘病毒 - 相关抗原或肿瘤相关抗原，以及药物组合物，包含重组寻求痘病毒和方法及其用途。在所提供的重组痘病毒增强先天和在受试者适应性免疫激活与缺少异源或天然的转录单位指定过量早期的dsRNA相同重组痘病毒。

8. 发明公开

EP1380651A2 Recombinant fowlpox virus with intact FPV-tk-gene 失效
标题翻译： Ein intaktes FPV-tk-Gen enthaltendes rekombinantes Virus der Vogelpocken
公开(公告)号：EP1380651A2
公开(公告)日：2004-01-14
申请号：EP03018689.4
申请日：1991-08-26
申请人： Baxter Healthcare S.A.
发明人： Dorner, Friedrich,Prof. Dr. , Scheiflinger, Friedrich, Dr. , Falkner, Falko Günter,Dr.
IPC分类号： C12N15/863
CPC分类号： C12N15/86 , A61K48/00 , A61K2039/5256 , C12N2710/24021 , C12N2710/24043
摘要： A process for producing a recombinant protein is described according to which vertebrate host cells or cell cultures are infected with a recombinant virus comprising a plasmid which comprises at least the FPV tk-gene, a downstream intergenic region and the following 3' open reading frame (3' orf) of fowlpox virus (FPV), wherein said intergenic region is modified to form an enlarged intergenic region which comprises one or more unique restriction sites thereby allowing insertion of foreign DNA in such a way that the FPV tk-gene remains intact and codes for the entire thymidine kinase (TK) and said recombinant virus comprises DNA coding for said protein.
摘要翻译：描述了用于产生重组蛋白质的方法，根据该方法，用含有至少包含FPV tk基因，下游基因间区域和下述3'开放阅读框架的质粒的重组病毒感染脊椎动物宿主细胞或细胞培养物 3'或ff），其中所述基因间区被修饰以形成扩增的基因间区，其包含一个或多个唯一的限制性位点，从而允许以使得FPV tk基因保持完整的方式插入外源DNA，整个胸苷激酶（TK）和所述重组病毒的编码包括编码所述蛋白质的DNA。

9. 发明公开

EP3055323A2 MALARIA VACCINATION 审中-公开
标题翻译： MALARIAIMPFUNG
公开(公告)号：EP3055323A2
公开(公告)日：2016-08-17
申请号：EP14784378.3
申请日：2014-10-13
申请人： Oxford University Innovation Limited , Academisch Ziekenhuis Leiden (also acting under the name of Leiden University Medical)
发明人： LONGLEY, Rhea , SALMAN, Ahmed , SPENCER, Alexandra , HILL, Adrian , JANSE, Chris , KHAN, Shahid
IPC分类号： C07K14/445 , A61K39/00 , A61K39/015
CPC分类号： A61K39/015 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/57 , A61K2039/575 , C07K14/005 , C07K14/445 , C12N7/00 , C12N15/86 , C12N2710/10021 , C12N2710/10022 , C12N2710/10023 , C12N2710/10034 , C12N2710/10043 , C12N2710/24021 , C12N2710/24022 , C12N2710/24023 , C12N2710/24034 , C12N2710/24043 , Y02A50/412
摘要： The invention relates to an antigenic composition or vaccine comprising a viral vector, the viral vector comprising nucleic acid encoding Plasmodium protein PfLSA1, or a part or variant of Plasmodium protein PfLSA1; PfLSAP2, or a part or variant of Plasmodium protein PfLSAP2; PfUIS3, or a part or variant of Plasmodium protein PfUIS3; PfI0580c, or a part or variant of Plasmodium protein PfI0580c; and PfSPECT-1, or a part or variant of Plasmodium protein PfSPECT-1.
摘要翻译：本发明涉及包含病毒载体的抗原组合物或疫苗，所述病毒载体包含编码疟原虫蛋白PfLSA1的核酸或疟原虫蛋白PfLSA1的部分或变体; PfLSAP2或疟原虫蛋白PfLSAP2的一部分或变体; PfUIS3或疟原虫蛋白PfUIS3的一部分或变体; PfI0580c，或疟原虫蛋白PfI0580c的一部分或变体; 和PfSPECT-1，或疟原虫蛋白PfSPECT-1的一部分或变体。

10. 发明公开

EP2900810A1 NOVEL MVA VIRUS AND USES THEREOF 有权
标题翻译：维也纳DAVON灭绝MVA-VIRUS
公开(公告)号：EP2900810A1
公开(公告)日：2015-08-05
申请号：EP12769398.4
申请日：2012-09-28
申请人： ProBioGen AG
发明人： JORDAN, Ingo , SANDIG, Volker
IPC分类号： C12N7/08 , C12N15/86
CPC分类号： C12N7/00 , C07K14/005 , C12N2710/24021 , C12N2710/24022 , C12N2710/24064 , C12N2710/24121
摘要： The present invention relates to a novel Modified Vaccinia Ankara (MVA) virus. The present invention also relates to a method for culturing said MVA virus and to a method for producing said MVA virus. Further, the present invention relates to a pharmaceutical composition comprising said MVA virus and one or more pharmaceutical acceptable excipient(s), diluent(s), and/or carrier(s). Furthermore, the present invention relates to a vaccine comprising said MVA virus. In addition, the present invention relates to said MVA virus for use in medicine.
摘要翻译：本发明涉及新型改良的牛痘安卡拉（MVA）病毒。本发明还涉及一种用于培养所述MVA病毒的方法和一种制备所述MVA病毒的方法。此外，本发明涉及包含所述MVA病毒和一种或多种药学上可接受的赋形剂，稀释剂和/或载体的药物组合物。此外，本发明涉及包含所述MVA病毒的疫苗。此外，本发明涉及用于医药的所述MVA病毒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式